Dr. Vladimir Lazar named “Outstanding Chief Operating Officer of the Year” for 2016-2017
Posted: Monday, June 06, 2016
Dr. Vladimir Lazar named "Outstanding Chief Operating Officer of the Year" for 2016-2017 by the International Society of Business Leaders (ISOBL)
NEW YORK, NY - 06/06/2016 (PRESS RELEASE JET) — The International Society of Business Leaders, ISOBL, New York proudly announces the nomination of Dr. Vladimir Lazar as “Outstanding Chief Operating Officer of the Year”, in recognition for the creation of the WIN Consortium.
The International Society Of Business Leaders announces today the nomination of Dr. Vladimir Lazar as “Outstanding Chief Operating Officer of the Year 2016”. This nomination comes in recognition of the accomplishments in the field of biotechnology and life sciences following the creation of the Worldwide Innovative Networking in Cancer Precision Medicine, WIN Consortium, which today is undeniably a unique organization at the forefront of the fight against cancer.
Dr. Vladimir Lazar obtained his MD (1989) at The University of Timisoara (Romania), First in Class and Certificate of Merit “Magna cum Laudae”. He became a specialist in Clinical Biology (DIS, 1997, University René Descartes in Paris) and obtained his PhD in molecular biology (1997) at The University René Descartes in Paris, with the highest degree and the Prize of University. Dr. Vladimir Lazar is specialized in clinical biology, molecular biology, molecular pathology and has a broad training, education and postgraduate degrees in biotechnology (first in class) and project management. He is a recognized specialist in translating research into clinical applications. He was the founder and Head of Gustave Roussy’s Genomic Center and Integrated Biology Platform (2002-2015) running the Agilent European reference and training center. He is the founder and Chief Operating officer of the WIN Consortium. In these positions he has built a strong expertise in project design, technology evaluation and implementation, use of genomics and biomarkers in oncology, companion test development, and biology driven clinical trials. He is author of 6 patents and author-co-author of more than 100 publications.
In 2010, Dr. Lazar initiated the WIN Consortium in Cancer Precision Medicine. The primary motivation for founding this new organization was triggered by the refusal of the status quo of oncology today. Despite undeniable recent progress, with new promising drugs and new therapeutic avenues, a staggering number of cancer patients remain diagnosed in late metastatic stage. This is painfully true in the case of lung cancer, which is mostly diagnosed at metastatic stage and remains incurable, with a high burden for the society.
‘’With so many patients and families hit by cancer, waiting for effective treatments, siloed research gets in the way of innovation. With WIN Consortium, academics and industries are working together in order to shift the paradigm of cancer care. WIN was founded on the premise that we can accomplish more together than each organization can achieve working alone. In WIN, Academics and Industries work hand in hand to develop the tools and therapies needed to significantly improve survival and quality of life of cancer patients from diverse backgrounds.’’ said Dr. Vladimir Lazar.
WIN Consortium is a non-profit, non-governmental organization incorporated in France that assembles all stakeholders of cancer care. 33 members: 25 renowned academics in 14 countries and 4 continents, 2 patient advocates and 6 industries (technology and pharma). The organization is led by an Executive Committee of renown global experts in the field:
- John Mendelsohn, Chairman, Director of Khalifa Institute for Personalized Cancer Medicine and Past-President, the University of Texas MD Anderson Cancer Center (USA),
- Richard L. Schilsky, Chairman Scientific Advisory Board, Chief Medical Officer ASCO (USA),
- Razelle Kurzrock, Head of Clinical Trials Committee – Chief, Division of Hematology & Oncology, Sr. Deputy Center Director for Clinical Science, University of California San Diego Moores Cancer Center (USA),
- Vladimir Lazar, Founder and Chief Operating Officer (France)
- Catherine Bresson, Director of Operations (UK)
For more information on Dr. Lazar please contact him
Vladimir Lazar, +33-66-109-15-22
Company Name: ISOBL
Full Name: STEPHANIE TAYLOR
Phone: 718 705 4936
Email Address: STAYLOR@ISOBL.COM
Diversity of Stakeholders - WIN Members
Studies with a global population
Sharing information to promote use of personalized, targeted cancer therapy: WIN Symposia
WIN was created to accelerate the pace and reduce the cost of translating novel cancer treatments to the bedside by developing and applying, through worldwide clinical trials and research projects, the most promising advances in genomic-based cancer research. WIN aims to initiate research projects each year in a global consortium guided by an independent scientific advisory board.
WIN now includes 35 institutional members. These stakeholders have come together from all parts of the world to address the challenge of increasing the efficacy of cancer diagnostics and therapeutics by understanding the genetics and biology of each individual’s tumor and accounting for genetic differences across diverse populations—from North and South America, Europe, Asia, and the Middle East.
Our goal is to significantly improve outcomes for patients around the globe. We aim to increase the number of patients worldwide that have access to innovative, global clinical trials in the area of genomic-based cancer therapeutics. Global diversity and inclusion of all stakeholders is WIN’s most important and differentiating asset.
Our members include leading academic, pharmaceutical, life science, not-for-profit, health IT, and healthpayer organizations.
WIN's first trial, WINTHER, is currently being carried out through a collaboration between six academic centers in five countries, with key support from Europe (EUFP7), Fondation ARC, Pfizer and other pharma companies.